Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging YearAccesswire • 03/28/23
Evotec SE to Announce Preliminary Financial Results for Fiscal Year 2022 on 28 March 2023Accesswire • 03/21/23
Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers SquibbAccesswire • 03/16/23
Evotec and Related Sciences Expand Integrated Drug Discovery and Development PartnershipAccesswire • 02/09/23
Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers SquibbAccesswire • 12/16/22
Evotec SE to Announce Results for the First Nine Months 2022 on 09 November 2022Accesswire • 11/03/22
Evotec, CDP Venture Capital and Angelini Ventures Launch Translational Partnership 'Extend' with Leading Italian Academic InstitutionsAccesswire • 10/28/22
Evotec Enters Partnership with Hannover Medical School to Create Molecular Patient Database in Autoimmune DiseasesAccesswire • 10/25/22
Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies ProgramAccesswire • 09/20/22
Evotec Initiates Ground-Breaking for New Biologics Facility J.POD(R) Toulouse, France (EU)Accesswire • 09/16/22
Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass GermanyAccesswire • 08/25/22
Evotec SE's (EVOTF) CEO Dr. Werner Lanthaler on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/13/22
Evotec SE Reports Results for the First Half-year 2022 and Provides Corporate UpdatesAccesswire • 08/11/22
Just - Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303Accesswire • 08/10/22